Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

Treatment
Home›Treatment›Failure of the immunotherapy agent in the NSCLC

Failure of the immunotherapy agent in the NSCLC

By Ramoju kishore kumar
August 7, 2018
565
0
Share:

Immunotherapy is a new kind of approach to treat cancer which works to harness the innate powers of the immune system and makes to fight against various diseases. This therapy is most efficient when compared to that of remaining therapies. Because it is based on targeted for systemic treatment and it has fewer side effects,When we compare this immunotherapy with that of chemotherapy . but immunotherapy does not have an perfect evidence regarding the disease cure.

Recently Bristol Myer Squibb (BMS)’s immunotherapy success, nivolumab (Opdivo), failed to improve progression-free survival (PFS) when given alone to treatment-naïve patients with non-small cell lung cancer (NSCLC) whose tumors expressed at least 5% of the biomarker programmed death-ligand 1 (PD-L1).

The trial was designed to evaluate the programmed death-1 (PD-1) inhibitor nivolumab as monotherapy against investigator’s choice of chemotherapy in patients with NSCLC. The trial enrolled 541 treatment-naïve patients whose tumors expressed PD-L1; patients were randomized to receive either a 3 mg/kg intravenous infusion of nivolumab, every 2 weeks or the physician’s choice of a chemotherapy agent. For patients with squamous NSCLC, the comparator treatment was one of the following:

  • Gemcitabine with cisplatin
  • Gemcitabine with carboplatin
  • Paclitaxel with carboplatin

In patients with non-squamous NSCLC, the comparator treatment was one of the following:

  • Pemetrexed with cisplatin
  • Pemetrexed with carboplatin

The trial endpoint was disease progression, unacceptable toxicity, or completion of 6 cycles of treatment. The primary endpoint was PFS.

Despite these disappointing results, chief executive officer Giovanni Caforio, MD, is hopeful about the other combination treatment trials that BMS is pursuing simultaneously.

“Opdivo has become a foundational treatment that is transforming cancer care across multiple tumor types. While we are disappointed CheckMate -026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase 3 CheckMate-227 study exploring the potential of the combination of Opdivo plus Yervoy for PD-L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD-L1 negative patients,” Caforio said in a press release.

TagscancerNSCLCProgrammed cell death
Previous Article

Propitious results from the new Alzheimer’s Drug.

Next Article

Tailoring Your Prescriptions: Pharmacist Architecture

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0
User Avatar

Ramoju kishore kumar

Related articles More from author

  • BLOGS

    US FDA approves first biosimilar for certain breast and stomach cancers treatment

    December 4, 2017
    By admin
  • BLOGS

    Immunotherapy as a best way for the cancer treatment

    October 20, 2017
    By admin
  • Medical research

    Pioneers in the medical field awarded with Nobel Prize

    October 2, 2018
    By Ramoju kishore kumar
  • Medical research

    Positive vibes for HPV vaccination study.

    September 25, 2018
    By Ramoju kishore kumar
  • DiseaseMedical & HealthMedical researchTreatment

    Polycystic ovary syndrome

    June 18, 2019
    By Sundari srinidhi
  • DiseaseMedical & HealthMedical researchTreatment

    Can Psoriasis increase the risk of Type 2 Diabetes

    November 25, 2018
    By Ramoju kishore kumar

Leave a reply Cancel reply

You may interested

  • BLOGS

    Spinal Cord Epidural Stimulation A Breakthrough Treatment Restores Voluntary Movement to Paralyzed Man’s Legs

  • Uncategorized

    Want a Successful Life, Dream it and Make it

  • Medical & Health

    Corona Vs Motherhood – IVF is helpful

  • LATEST REVIEWS

  • TOP REVIEWS

  • Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • August 3, 2023

    List of UGC declared 20 universities as fake, not authorised to award degrees.

  • July 28, 2023

    Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

  • May 24, 2021

    LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

  • October 20, 2020

    List of UGC Approved journals 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

Latest Comments

  • Sowmya V
    on
    December 13, 2019
    Nice keep it up

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC declared 20 universities as fake, not authorised to award degrees.

    By mythandintegrity
    August 3, 2023
  • Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

    By mythandintegrity
    July 28, 2023
  • LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

    By admin
    May 24, 2021
  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    By Sundari srinidhi
    December 12, 2019
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • Sowmya V
    on
    December 13, 2019

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    Nice keep it up

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.